The malaria diagnostics market is expected to touch USD 0.82 billion by 2032, growing at 5.7% from 2023 to 2032. Many variables shape the Malaria Diagnostics Market and drive its development. Infected mosquitoes spread Plasmodium parasite-caused malaria, a lethal disease. The worldwide malaria load is a major factor. Malaria detection technologies must be accurate and fast for disease management, treatment, and prevention. Malaria continues to affect endemic communities; thus precise and fast diagnostic technologies are needed.
Rapid diagnostic tests (RDTs), molecular diagnostics, and microscopy advances make diagnostic equipment more sensitive, specific, and user-friendly. Point-of-care testing and new technologies like nucleic acid amplification and biosensors have increased malaria detection speed and accuracy. This is especially true in resource-poor, disease-endemic areas.
The World Health Organization (WHO) and the Roll Back Malaria Partnership are leading malaria control efforts that emphasize the need of precise diagnosis. In nations with the illness, governments typically start mass screening and treatment programs, increasing the demand for inexpensive and scalable diagnostic options. Regulatory frameworks and quality assurance are essential for malaria diagnostic technology reliability and efficacy.
Due to drug-resistant strains and fluctuating transmission patterns, malaria epidemiology demands flexible diagnostic tools. The diagnostic equipment must detect P. falciparum, the deadliest Plasmodium species, and P. vivax, another frequent parasite. The invention and implementation of malaria diagnostics need the flexibility to distinguish between species and assess drug resistance trends to identify effective treatment options.
In low-resource areas, pricey diagnostic technology may be hard to acquire and utilize. Decentralized and community-level testing requires fast, cost-effective diagnostic procedures like quick diagnostic tests. These diagnostic technologies reach malaria-stricken regions thanks to donor money, global collaborations, and government subsidies.
Major factors affecting the Malaria Diagnostics Market are competition and consolidation. Established diagnostic companies, new competitors, and strategic collaborations make the industry competitive. Diagnostic companies may expand their market presence and product distribution by partnering with governments, NGOs, and international agencies. Competitive dynamics affect malaria diagnostic equipment availability, product development, and cost.
The Malaria Diagnostics Market Size valued at USD 0.045 Billion in 2023. The Malaria Diagnostics industry is projected to rise from USD 0.047 Billion in 2024 to USD 0.082 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 6.23% during the forecast period (2024 - 2032).
Malaria is a parasitic disease conveyed by the bite of infected anopheles mosquitoes. The Plasmodium parasite is transmitted by infected mosquitos. The parasite is released into the circulation after being bitten by an infected mosquito. When the human body becomes the parasite's host, the parasite grows in the liver. The adult parasite enters the bloodstream and infects red blood cells after a few days. Fever, vomiting, weakness, and headache are common symptoms of malaria in humans. In recent years, the global market for malaria diagnostics has grown dramatically.
The market's expansion is mostly due to developments in technological innovations in diagnostic instruments, as well as rising demand for treatment in malaria-endemic nations. Furthermore, factors such as increased collaboration between research institutes and industry, as well as government funding, are expected to support market expansion in the estimated timeframe. Factors such as a lack of solid import-export rules, lack of knowledge, a weak regulatory framework, and a lack of suitable monitoring standards at the country level, on the other hand, are expected to limit the market's growth in the next years.
The market of malaria diagnostics has been segmented on the basis of technology and end-user.
On the basis of technology, the market has been classified as rapid diagnostic tests, microscopy, and molecular diagnostic tests. The molecular diagnostics tests are segmented into polymerase chain reaction (PCR) and real-time polymerase chain reaction (RT-PCR).
On the basis of end-users, the market has been classified as hospitals, clinics, community healthcare, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The malaria diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The malaria diagnostics market in the Middle East and Africa has been segmented into the Middle East and Africa.
In the global market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. In 2016, global governments of malaria-endemic countries have invested USD 2.7 billion in malaria control and elimination efforts. The US was the largest contributor by providing USD 1 billion for the eradication of malaria.
The European market is expected to hold the least share due to the growing number of malaria-free countries in the region.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The Asia-Pacific remains to be the second largest burden of malaria globally with 22 malaria-endemic countries accounting for roughly 28 million cases and 45,000 deaths every year. The WHO figures say that in the Asia-Pacific region, Myanmar, Pakistan, India, and Indonesia carry the highest malaria burden accounting for 89% of all malaria cases in the region.
The market in the Middle East and Africa is expected to account for the smallest share of the global malaria diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Sub-Saharan Africa remains to bring an excessively high share of the global malaria burden on the Middle Eastern and African market. the region was home to 90% of malaria incidences and 92% of malaria deaths in 2015
Malaria Diagnostics Market Key Players
Some of the key players in the global market are
Recent Development
In March 2022, Audere, a digital health foundation dedicated to improving global health, announced a partnership with Medical Diagnostech, a designer and manufacturer of lateral flow fast diagnostic test kits. Medical Diagnostech's MD SARS-nCoV-2 Antigen Device1 will be paired with Audere's HealthPulsedigital companion app as part of the agreement. In February 2022, Kemri released the first domestically produced malaria and Covid-19 test kits. Both were freed by Health CAS Rashid Aman. Researchers of the Kenya Medical Research Institute created them. According to Aman, they have performed between three and four million Covid-19 tests thus far, and they are expensive. The ministry will assist the company with manufacturing and will be the product's primary consumer.
Americas
Europe
Asia-Pacific
Middle East & Africa
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)